After years of research, we can now modulate how the microbiota influence lung diseases. The commercialization of this work from University of Alabama at Birmingham, led by ResBiotic founder and Chief Scientific Officer C. Vivek Lal MD FAAP, has the potential to be life changing for respiratory disease patients.